India Pharma Outlook Team | Monday, 17 November 2025
Alembic Pharmaceuticals experienced an increase of 3.07%, reaching Rs 930.50, following the announcement that it has obtained final approval from the USFDA for its ANDA concerning Diltiazem Hydrochloride tablets.
This approval encompasses strengths of 30 mg, 60 mg, 90 mg, and 120 mg. The product represents the generic variant of Cardizem, marketed by Bausch Health. This medication is utilized for the management of chronic stable angina as well as angina induced by coronary artery spasm.
Alembic stated that this approval enhances its robust portfolio in the United States. The company now holds a total of 230 ANDA approvals, which consist of 210 final approvals and 20 tentative approvals.
Also Read: Pfizer Completes Metsera Deal to Expand Obesity Drug Pipeline
Alembic Pharmaceuticals operates as a vertically integrated pharmaceutical company focused on research and development. It manufactures and distributes generic pharmaceutical products globally.
The consolidated net profit of the company surged by 20.40%, amounting to Rs 184.71 crore in Q2 FY26, in comparison to Rs 153.41 crore reported in Q2 FY25. Revenue from operations increased by 15.90% year on year (YoY), reaching Rs 1,910.15 crore in Q2 September 2025.
The company functions as a vertically integrated global pharmaceutical entity with robust capabilities in formulations, active pharmaceutical ingredients (APIs), and international generics, catering to both regulated markets such as the U.S. and domestic branded segments across various therapeutic areas, including cardiovascular, ophthalmology, gynecology, dermatology, and oncology.
Alembic is recognized for its significant investment in research and development, bolstered by FDA-approved facilities and a bio-equivalence center that facilitates consistent ANDA submissions and expansion into complex generics.
